Targeting the PI3K/AKT signaling pathway with PNU120596 protects against LPS-induced acute lung injury.

This article investigates the therapeutic potential of PNU120596, a positive allosteric modulator of the α7 nicotinic acetylcholine receptor (α7nAChR), in reducing acute lung injury (ALI) induced by lipopolysaccharide (LPS) in a mouse model. The study demonstrates that PNU120596 dose-dependently ameliorates lung injury, improves lung function, and suppresses inflammatory responses and oxidative stress by inhibiting the activation of the phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathway. Both in vivo and in vitro experiments with alveolar macrophages confirmed that PNU120596 reduces pro-inflammatory cytokine production and PI3K/AKT pathway activation, effects reversed by the PI3K/AKT activator Recilisib. These findings suggest that modulation of α7nAChR with PNU120596 may offer a novel strategy for ALI treatment, although further research is needed to validate optimal dosing and clinical applicability.